AMAC Supports Bill to Utilize Biosimilars to Lower Drug Costs for Medicare Program

S. 4134 works to lower out-of-pocket expenses for medications by promoting competition and increasing access to biosimilars. It also complements President Trump’s recent Executive Order signings designed to lower prescription drugs for Americans.

August 5, 2020

The Honorable John Cornyn
Senator from Texas
517 Hart Senate Office Building
Washington, DC 20510

Dear Senator Cornyn,

On behalf of the 2.2 million members of AMAC – Association of Mature American Citizens, including over 191,000 residing in Texas, I write to offer our support for S. 4134, the Increasing Access to Biosimilars Act.

As an organization representing numerous Americans who are Medicare beneficiaries, the high cost of prescription drugs continues to be a major concern for AMAC members. We have heard of many instances where our members resort to compromising other expenditures or stretching their medication regimen to accommodate the cost of their prescriptions.

The Increasing Access to Biosimilars Act calls for a shared savings demonstration program for biosimilar drugs in the Medicare program. Biosimilars are highly similar to already approved biological medications and are demonstrated to be safe and efficacious. Your bill would also work to lower out-of-pocket expenses for medications by promoting competition and increasing access to biosimilars.

Thank you, Senator Cornyn, for introducing bipartisan legislation that complements President Trump’s recent Executive Order signings designed to lower the cost of prescription drugs. Your bill would expand lower-cost medication options for seniors and physicians and AMAC is pleased to offer our organization’s full support for S. 4134, the Increasing Access to Biosimilars Act.

Sincerely,

Bob Carlstrom
President,
AMAC Action